November 22, 2016 5:24pm
… The sector opened positive, fell off the cliff at 10:30 am, kept going down at the mid-day and closed depressed …
The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.36% and closed UP +0.91% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open positive +0.17% and closed DOWN -1.87%.
I answer one question; in which company should investors put, keep and commit their money!
Pre-open indication’s tally: 6 hits (AST, BLCM, CAPR, IMUC, KITE and OPXA) and 0 miss
Lose an advantage or be a subscriber! Today’s results have implications to Wednesday's sector activity.
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. equities closed higher on Tuesday, hitting new all-time highs, as investors digested housing data and kept an eye on President-elect Donald Trump's policy agenda.
The NASDAQ closed UP +17.49 or +0.33% to 5,386.35 and the DOW closed UP +67.18 or +0.35% to 19,023.87.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 21/10 and 4 flats;
- The mid-day stayed negative with an A/DL of 10/33 and 0 flat;
- The closing bell was negative with A/DL of 14/26 and 3 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened positive, dumped negative at the mid-day and closed negative.
- From this morning’s investor’s letter, “Highs have a way of depreciating! After the past the past five sessions; I’d be “booking” any gain and departing for Thanksgiving as early as I could get away …”
The S&P 500 traded over 2,200 for the first time, as telecommunications rose about 2.1%. But a nearly 1.6% fall in health care stocks pushed the index to around breakeven. The NASDAQ composite had also risen to all-time highs, before holding 0.17% higher.
- The three major indexes closed at record levels on Wednesday, along with the small-caps Russell 2000, which continues to outperform the Dow, S&P and NASDAQ since Nov. 8.
The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.36% and closed UP +0.91% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open positive +0.17% and closed DOWN -1.87%.
- The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded slightly lower, near 12.6.
Markets will be shut on Thursday and then close early on Black Friday, the traditional kickoff to holiday shopping.
At the close …
Gainers included Fate Therapeutics (FATE +$0.28), Cesca Therapeutics (KOOL +$0.22), Stemline (STML +$0.15), ReNeuron (RENE.L +$0.125), AxoGen (AXGN +0.10) and Fibrocell (FCSC +$0.068) contributed the most gains;
The biggest losers of the session were Spark therapeutics (ONCE -$2.38), Kite Pharma (KITE -$1.99), Bellicum (BLCM -$1.87), Juno Therapeutics (JUNO =$1.56) and bluebird bio (BLUE -1.55)
The downside trend reflects a pricing trend range of:
- Tuesday’s decliners ranged from – 0.16% <CAPR> to -28.57% <OPXA> in 26 equities;
- Monday’s decliners ranged from -0.58% <XON> to -15.49% <ADVM> in 15 equities;
- Friday’s decliners ranged from -0.31% <ONVO>to -12.34% <NWBO>in 17 equities
- Thursday’s decliners ranged from -0.78% <JUNO> to-21.28% <STEM> in 15 equities;
- Wednesday’s decliners ranged from -0.42% <STML> to -14.93% <IMUC> in 26 equities;
- Last Tuesday’s decliners ranged from -0.02% <OPXA> to -9.52% <RENE.L> in 27 equities;
The upside shows a pricing trend range of:
- Tuesday’s gainers ranged from +0.26% <VTGN> to +10.53% <FATE> in 14 equities;
- Monday’s gainers ranged from +0.14% <QURE> to +4831.3% (IMUC – after a reverse split> in 26 equities;
- Friday’s gainers ranged from +0.21% <MESO> to +21.82% <OPXA> in 24 equities;
- Thursday’s gainers ranged from +0.14% <IMUC> to +12.50% in 28 equities;
- Wednesday’s gainers ranged from +0.46% <OSIR> to +31.78% <STEM> to in 13 equities;
- Last Tuesday’s gainers ranged from +0.58% <AXGN> to +11.11% <CLBS> in 13 equities
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers.
- Tuesday’s 14 gainers followed Monday’s 26 gainers compared to Friday’s 24 following Thursday’s 28 following Wednesday’s 13 post last Tuesday’s 13 …
- Tuesday’s 26 decliners followed Monday’s 15 after Friday’s 17 as compared to Thursday’s 15 following Wednesday’s 26 after last Tuesday’s 27...
Pre-open indication’s tally: 6 hits (AST, BLCM, CAPR, IMUC, KITE and OPXA) and 0 miss
- Asterias Biotherapeutics (NYSEMKT: AST) closed DOWN -$0.25 – hit;
- Bellicum Pharmaceuticals (BLCM) closed DOWN -$1.87 – hit;
- Capricor (CAPR) closed UP +$0.00 – hit;
- ImmunoCellular (NYSEMKT: IMUC) closed DOWN -$0.11 – hit;
- Kite Pharma (KITE) closed DOWN -$1.99 – hit;
- Opexa (OPXA) closed DOWN -$0.42 – hit;
Percentage decliners:
- Opexa (OPXA) -28.57% after Monday’s +119.4% after Friday’s +21.82% after Thursday’s -6.76% after Wednesday’s +5.34%;
- Bellicum (BLCM) -8.20%;
- Neuralstem (CUR) -7.11% after Monday’s -4.11%;
- uniQure (QURE) -6.45%;
- Regenxbio (RGNX) -5.34%
Percentage advancers:
- Fate Therapeutics (FATE) +10.53%;
- Northwest Bio (NWBO) +8.95% after Monday’s +8.06% after Friday’s -12.34%;
- Fibrocell (FCSC) +7.80% after Monday’s +7.15% after Friday’s +13.42%;
- Cesca Therapeutics (KOOL) +7.36% after Monday’s -6.85% after Friday’s -5.31% after Thursday’s +7.62%;
- ReNeuron (RENE.L) +5.06%
Flat:
- Biostage (BSTG) at $0.84;
- Caladrius Biosciences (CLBS) at $4.17;
- Organovo (ONVO) at $3.19
Review my fear gauge or the CBOE Volatility Index (VIX):
· Tuesday traded near 12.6;
· Monday traded 12.5;
· Friday traded near 13.2;
· Thursday traded near 13.5;
· Wednesday traded near 13.9;
· Last Tuesday traded near 13.4;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
